Berlin, Germany, February 25, 2020. The aim of the Optical Fiber Dose Imaging for Adaptive Brachytherapy (ORIGIN) project is to develop a new optical fiber-based sensor system for real-time radiation dose imaging and source localization. Applicable for low-dose-rate and high-dose-rate brachytherapy, the resulting in vivo dosimetry system is expected to enhance dose measurement resolution and verification during the treatment of prostate and gynecological cancers.
With more than 10 years of experience in the integration of in vivo dosimetry into the gynecological HDR treatment workflow, Eckert & Ziegler BEBIG is proud to be part of this consortium to take dose verification to the next level. The company´s HDR afterloaders, MultiSource and GyneSource, as first generation, and SagiNova® as latest generation, are the only systems in the brachytherapy market that integrate hardware and software of in vivo dosimetry components directly into the afterloader. This enables coherent quality assurance, probe calibration, dose monitoring, dose warnings and dose reporting directly in the afterloader system, with minimal effect on usability. More than 30% of Eckert & Ziegler BEBIG´s afterloader users have one of the integrated in vivo dosimetry systems and this number is expected to increase further with a new integrated real-time radiation dose imaging and source localization system for both gynecological and prostate brachytherapy treatments.
Eckert & Ziegler BEBIG´s SagiNova® HDR Afterloader with integrated In Vivo Dosimetry
Regarding low-dose-rate (LDR) brachytherapy, Eckert & Ziegler BEBIG has established itself as the market leader for LDR prostate brachytherapy in Europe. The sustainable enhancement of the IsoSeed® designs constantly considers the optimization of seed visibility for standard imaging methods. The improvement in the field of dose verification targeted in the ORIGIN project promises a further increase in the already excellent LDR brachytherapy treatment results, especially as re-gards the quality of life achieved for patients after the implantation of the seeds*.
The ORIGIN project is an initiative of the Photonics Public Private Partnership and is funded by the European Union's Horizon 2020 Research and Innovation Program, which supports European in-novation initiatives in public and private sectors. As of January 1, 2020, ORIGIN will be led by the University of Limerick and, in addition to Eckert & Ziegler BEBIG, Vrije Universiteit Brussels, DoseVue N.V., Queens University Belfast, Centre Antoine Lacassagne, Galway Clinic, and Università Degli Studi Dell'Insubria are taking part in the research and development activities.
The ORIGIN project is an initiative of the Photonics Public Private Partnership (www.photonics21.org), and has received funding from the European Union's Horizon 2020 Re-search and Innovation Program under Grant Agreement No. 871324.
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a global provider of radiotherapy products and a leader in brachytherapy in Europe. The company’s offices and subsidiaries are located throughout Europe, Asia, and the United States. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product lines. In recent years, Eckert & Ziegler BEBIG has grown through the acquisitions of US-based Mick Radio-Nuclear In-struments, Inc. and the x-ray device manufacturer WOLF-Medizintechnik GmbH (WOmed). Eckert & Ziegler BEBIG is the oldest subsidiary of the Eckert & Ziegler Group. The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific, and industrial use. The core businesses of the Group are cancer therapy, industrial radiometry, and nuclear-medical imaging.
Eckert & Ziegler BEBIG Contact Person:
Marketing Communication Manager